SciClone Pharmaceuticals Gains FDA Nod for Thymalfasin COVID-19 Vaccine Booster Study
SciClone Pharmaceuticals Inc. (HKG: 6600), formerly a US-based and Nasdaq-listed company, has announced that it...
Drug
Hainan Poly Pharm’s PL002 Accepted for FDA Review for Liver Cancer Surgery
China-based pharmaceutical company Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that the Investigational...
Pfizer’s Velsipity Approved by FDA for Ulcerative Colitis Treatment
China-based pharmaceutical company Everest Medicines (HKG: 1952) announced that its licensing partner, Pfizer Inc. (NYSE:...
FDA Approves Pfizer’s Braftovi + Mektovi Combo for BRAF V600E Metastatic NSCLC
The US Food and Drug Administration (FDA) has granted Pfizer (NYSE: PFE) regulatory approval for...
Roche’s Ocrevus Demonstrates Long-Term Efficacy in Multiple Sclerosis Treatment
Swiss pharmaceutical giant Roche (SWX: ROG) has presented compelling long-term efficacy data for its selective...
Sichuan Huiyu Pharmaceutical’s HYP2090PTSA Gains NMPA Approval for KRAS G12C Solid Tumors
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...
AbbVie’s Rinvoq Demonstrates Sustained Efficacy in Late-Stage Atopic Dermatitis Study
AbbVie (NYSE: ABBV) has announced late-stage results for its JAK inhibitor Rinvoq (upadacitinib) in the...
Lee’s Pharmaceutical’s Subsidiary Announces Positive Results for Myopia Treatment NVK002
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622),...
J&J’s Cetrelimab and TAR-200 Gain Tacit Approvals for Bladder Cancer Trials
The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J; NYSE:...
RemeGen Secures NMPA Approval for Phase II Study of Disitamab Vedotin in Breast Cancer
China-based biopharma RemeGen Ltd (HKG: 9995) has announced that it has received approval from the...
Ascentage Pharma Initiates Phase III Study for APG-2575 and Calquence in CLL/SLL
Suzhou-based Ascentage Pharma (HKG: 6855) has announced the approval to commence a global multi-center, randomized,...
Betta Pharmaceuticals Secures NMPA Approval for Befotertinib in NSCLC Treatment
China-based Betta Pharmaceuticals Co., Ltd. (SHE: 300558) has officially announced its receipt of market approval...
KPC Pharmaceuticals Secures WHO Prequalification for Dihydroartemisinin/Piperaquine
Yunnan-based KPC Pharmaceuticals Inc. (SHA: 600422) has announced that its dihydroartemisinin/piperaquine 40mg/320mg formulation has received...
MSD’s Keytruda Achieves Primary Endpoint in Late-Stage NSCLC Trial
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...
Novo Nordisk Halts Phase III Ozempic Study on Renal Impairment in Diabetes Patients
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has decided to discontinue a Phase III global...
Henlius Pharmaceutical Secures GMP Compliance for PD-1 Inhibitor Serplulimab in Indonesia
Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced that its partner, PT Kalbe Genexine...
Yiling Pharmaceutical Secures NMPA Approval for Phase I Study of G201-Na in Premenopausal Women
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received approval from...
GenFleet Therapeutics’ CDK9 Inhibitor SLS009 Earns Orphan Drug Status for AML
Shanghai-based biotechnology company GenFleet Therapeutics has announced that its CDK9 inhibitor, SLS009 (GFH009), has received...
Roche’s Forimtamig Receives Tacit Approval for Multiple Myeloma Clinical Trials
The Center for Drug Evaluation (CDE) has indicated that Swiss pharmaceutical giant Roche (SWX: ROG)...
Janssen Unveils Promising Clinical Data on IL-23 Blockers for Psoriasis
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) is showcasing new clinical data...